Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ERNA

Eterna Therapeutics Inc

May 01 • 04:00PM ET

1.78

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.08	Insider Own	44.89%	Shs Outstand	5.41M	Perf Week	2.30%
Market Cap	9.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.98M	Perf Month	-22.61%
Income	-21.68M	PEG	-	EPS next Q	-	Inst Own	16.19%	Short Float	1.34%	Perf Quarter	4.71%
Sales	0.07M	P/S	137.57	EPS this Y	-	Inst Trans	-22.53%	Short Ratio	4.59	Perf Half Y	29.93%
Book/sh	0.41	P/B	4.31	EPS next Y	-	ROA	-60.69%	Short Interest	0.04M	Perf Year	-38.79%
Cash/sh	1.40	P/C	1.27	EPS next 5Y	20.00%	ROE	-302.20%	52W Range	0.84 - 3.45	Perf YTD	-0.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.06%	ROI	-51.80%	52W High	-48.41%	Beta	4.52
Dividend TTM	-	Quick Ratio	1.46	Sales past 5Y	-23.02%	Gross Margin	-1825.00%	52W Low	111.88%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	1.46	EPS Y/Y TTM	50.02%	Oper. Margin	-30404.41%	RSI (14)	34.89	Volatility	6.94% 7.58%
Employees	8	Debt/Eq	18.76	Sales Y/Y TTM	-	Profit Margin	-31888.24%	Recom	1.00	Target Price	60.00
Option/Short	No / Yes	LT Debt/Eq	17.77	EPS Q/Q	-11.46%	Payout	-	Rel Volume	0.00	Prev Close	1.78
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	8.74K	Price	1.78
SMA20	-13.62%	SMA50	-13.13%	SMA200	-7.98%	Trades		Volume	0	Change	0.00%

Mar-15-24 08:53AM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors (GlobeNewswire)
Jan-03-24 04:15PM	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (GlobeNewswire)
Dec-21-23 11:18AM	Eterna Therapeutics Appoints Sanjeev Luther as President and CEO (Exec Edge)
Dec-20-23 04:15PM	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer (GlobeNewswire) +9.87%
06:56PM	Loading…
Dec-14-23 06:56PM	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing (GlobeNewswire) +29.29%
Nov-02-23 11:48AM	Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors (Exec Edge) +8.13%
Nov-01-23 08:30AM	Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors (GlobeNewswire) -12.76%
Sep-06-23 01:01PM	Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies (Exec Edge)
09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics (GlobeNewswire)
Sep-05-23 11:24AM	Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors (Exec Edge)
08:30AM	Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors (GlobeNewswire)
Jul-18-23 02:24PM	Eterna Therapeutics Announces $8.7M Private Placement Transaction (Exec Edge) +8.89%
08:00AM	Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing (GlobeNewswire)
11:21AM	Loading…
Jul-11-23 11:21AM	Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors (Exec Edge) +6.52%
08:30AM	Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors (GlobeNewswire)
May-24-23 11:18AM	Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel (Exec Edge) -5.41%
08:30AM	Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel (GlobeNewswire)
May-17-23 08:30AM	Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) -5.73%
May-04-23 08:30AM	Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-03-23 01:40PM	Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis (Exec Edge)
May-02-23 07:30AM	Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics (GlobeNewswire)
Apr-11-23 08:00AM	Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million (GlobeNewswire)
Mar-28-23 08:30AM	Jeff Karp, Ph.D., Joins Eternas Scientific Advisory Board (GlobeNewswire)
Mar-20-23 04:10PM	Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights (GlobeNewswire) -7.74%
Mar-16-23 07:04AM	Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m (Simply Wall St.) +10.00%
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (GlobeNewswire)
Jan-04-23 08:30AM	Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President (GlobeNewswire) +8.06%
08:05AM	Loading…
Dec-20-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics (ACCESSWIRE)
Nov-01-22 08:30AM	Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies (GlobeNewswire)
Oct-18-22 08:30AM	Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress (GlobeNewswire) +10.98%
Oct-17-22 08:30AM	Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics (GlobeNewswire) +19.94%

Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERNA

Eterna Therapeutics Inc

Upgrade your FINVIZ experience